Open AccessVisfatin Levels in Nonalcoholic Fatty Liver Disease
Author(s) -
Akbal Erdem,
Koçak Erdem,
Taş Adnan,
Yüksel Enver,
Köklü Seyfettin
Publication year - 2012
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.21491
Subject(s) - nonalcoholic fatty liver disease , adiponectin , medicine , insulin resistance , fatty liver , endocrinology , leptin , autoimmune hepatitis , hepatitis , viral hepatitis , pathogenesis , metabolic syndrome , gastroenterology , disease , insulin , obesity
Purpose Recently, role of adipokin in the pathogenesis of nonalcoholic fatty liver disease ( NAFLD ) has been suggested. Among adipokins, role of leptin and adiponectin is rather well known; however, there are only a few data concerning visfatin. Material and Methods NAFLD is confirmed in 30 patients by ultrasonography. As a control group, patients without fatty liver or other liver diseases were included. Viral hepatitis, metabolic liver diseases, and autoimmune hepatitis and consumption of alcohol were excluded in all patients. Fasting serum level of visfatin was determined by ELISA method. Results Serum visfatin concentration in the NAFLD group (14.7 ± 8.1 ng/ml) was significantly higher than in controls (9.4 ± 1.6 ng/ml) ( P < 0.001). There were no correlations between visfatin and anthropometric parameters, transaminases, lipids, and homeostasis model assessment‐estimated insulin resistance ( HOMA‐IR ). Conclusion Serum visfatin concentration increases in patients with NAFLD .